Semax (ACTH Fragment Peptide)

What Is Semax? Origin, Sequence and Neurotrophin Mechanism

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It combines a four-residue fragment of ACTH with a Pro-Gly-Pro extension that confers stability and removes the parent hormone's adrenal-stimulating activity.

Key facts

Sequence
H-Met-Glu-His-Phe-Pro-Gly-Pro-OH
Single-letter
MEHFPGP
Length
7 residues (heptapeptide)
Molecular weight
813.9 Da
Molecular formula
C37H51N9O10S
CAS number
80714-61-0
PubChem CID
9811102
Origin
Institute of Molecular Genetics, RAS
Western approval
None (not MHRA, EMA or FDA approved)

Where it comes from

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its design starts from adrenocorticotropic hormone, a 39-residue pituitary hormone, and takes a short N-terminal-region fragment of it. The peptide has been registered as a prescription medicine in the Russian Federation since the 1990s, and is not approved by any Western regulator.

The Pro-Gly-Pro extension does two jobs

This is the design feature that defines the molecule. Appending Pro-Gly-Pro to the ACTH fragment sharply increases resistance to enzymatic degradation, because proline-rich sequences are poor substrates for most peptidases. It also removes the steroidogenic activity of the parent hormone. Semax does not stimulate adrenal steroid production, which is what separates it pharmacologically from ACTH itself.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Reported mechanism

The published work centres on neurotrophins. Semax has been reported to upregulate expression of brain-derived neurotrophic factor and nerve growth factor, with downstream signalling through their TrkB and TrkA receptors. Additional reported activity includes modulation of dopaminergic and serotonergic transmission and interaction with the endogenous opioid system. Most of this is rodent work.

The evidence base, described accurately

PubMed indexes roughly 231 records. The mechanistic literature includes work in Brain Research, BMC Genomics and the Journal of Molecular Neuroscience, and is largely conducted in rats. The clinical literature is substantially published in Russian-language journals, principally the Korsakov Journal of Neurology and Psychiatry, and much of it predates current trial-reporting standards. That is a description of where the evidence sits, not a dismissal of it.

Regulatory position

Registration in the Russian Federation is a fact about a decision made by a national regulator. It confers nothing outside that jurisdiction. Semax holds no marketing authorisation from the MHRA, EMA or FDA, cannot be prescribed or dispensed in the UK, and is supplied here for laboratory research only.

Frequently asked questions

Is Semax approved in the UK?

No. It is registered as a prescription medicine in the Russian Federation but holds no MHRA, EMA or FDA authorisation, and is supplied for laboratory research only.

How large is the Semax literature?

Around 231 indexed PubMed records. The mechanistic work is largely rodent; the clinical work is largely Russian-language.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.